IMRN News and Press, Immuron Limited From 01/17/22

MELBOURNE, Australia, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that...

MELBOURNE, Australia, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pathogens, is pleased to announce that...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, one of the best-performing stocks in the market is  Immuron  (NASDAQ: IMRN ). At the time of writing, IMRN stock has soared more than 40% on extremely high volume. Source: luchschenF / Shutterstock.c...

Immuron Limited ( NASDAQ: IMRN ) went up 30% after it announced that it had received $6.2 million from the Department of Defense to conduct clinical research on a dosing regimen for Travelan. This new research agreement with the DoD aims to confirm and test the efficacy of d...

Immuron Limited (NASDAQ: IMRN) has announced funding of a new research agreement with the United States Department of Defense.  This agreement, titled “Biologics License Application (BLA) of a therapeutic Bovine Immunoglobulin supplement targeting Travelers’...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! Let’s get this party started with a dive into the biggest pre-market stock movers for Wednesday! Source: Eric Urquhart/Shutterstock.com We’ve got financing deals, preliminary Q4 r...

Key Highlights: Immuron Awarded AU $4.8 (USD $3.43) million funding by the U.S. Department of Defense for Travelan U.S Naval Medical Research Center Received AU $1.4 (USD $1.02) million funding to support the Travelan clinical development effort Tot...

Key Points Manufacture of investigational medical products to support the Uniformed Services University (USU) clinical program to evaluate the efficacy of Travelan® and two other non-antibiotic OTC products in Travelers’ Diarrhea initiated ...

Key Points Manufacture of investigational medical products to support the US Naval Medical Research Centre (NMRC) clinical programs completed. IND submission to the U.S. Food and Drug administration (FDA) planned for Q1 CY2022 to support Two human phase II clin...

ChemoCentryx CCXI +71% on FDA approval of Tavneos for treatment of vasculitis (updated) Camber Energy (NYSE:CEI) +33%. eFFECTOR Therapeutics EFTR +22% after-hours on encouraging zotatifin data in breast cancer InflaRx N.V. (NASDAQ:IFRX) +18%. Immuron (NASDAQ:IMRN) +16%. Fo...